A somewhat paradoxical link comes from melanoma patients placed on BRAF inhibitors, who subsequently develop cSCCs resulting from the superactivation of MAPK in skin epithelial cells that are wild type for BRAF (Flaherty et al. 2012; Oberholzer et al. 2012; Su et al. 2012). The gene discussed is BRAF; the disease is melanoma.